Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26742799 | 0.85 | HTT (0.46) | ALDH1A1TDP1POLBSIGMAR1KDM4E | |
| SCHEMBL29328244 | 0.85 | TSHR (0.36) | ALDH1A1POLBSIGMAR1KMT2ACYP3A4 | |
| SCHEMBL29328262 | 0.82 | HTR4 (0.37) | ALDH1A1TDP1POLBKDM4EHTR4 | |
| SCHEMBL29342424 | 0.81 | KDM4E (0.38) | ALDH1A1TDP1POLBKDM4EKMT2A | |
| SCHEMBL29328227 | 0.79 | CHRM5 (0.43) | ALDH1A1TDP1POLBL3MBTL1SIGMAR1 | |
| SCHEMBL29342761 | 0.78 | ALDH1A1 (0.43) | ALDH1A1TDP1POLBL3MBTL1SIGMAR1 | |
| SCHEMBL29328061 | 0.77 | CHRM5 (0.49) | ALDH1A1TDP1POLBSIGMAR1KDM4E | |
| SCHEMBL21906821 | 0.74 | HTR4 (0.42) | POLBKMT2AHTR4CYP3A4MEN1 | |
| SCHEMBL26741589 | 0.74 | ALDH1A1 (0.46) | ALDH1A1TDP1POLBL3MBTL1SIGMAR1 | |
| SCHEMBL29316594 | 0.74 | HTT (0.45) | ALDH1A1TDP1POLBSIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | ALDH1A1 1138/4885TDP1 535/4885POLB 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.